India, Dec. 18 -- Praxis Precision Medicines, Inc. (PRAX), a clinical-stage biopharmaceutical company, announced on Wednesday, that the FDA granted Rare Pediatric Disease Designation for its investigational drug Relutrigine in Dravet syndrome.
Dravet syndrome is a severe, progressive genetic epilepsy that typically begins within the first year of life. The condition is characterized by frequent, prolonged, and treatment-resistant seizures, leading to intellectual disability, developmental delays, and other neurological impairments.
Relutrigine, a first-in-class small molecule, works by preferentially inhibiting persistent sodium current, which is a key driver of seizure symptoms in developmental and epileptic encephalopathies (DEEs) like ...